Literature DB >> 12594936

Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer.

Elizabeth Swisher1.   

Abstract

The goal of a cancer prevention program is to improve the mortality rates of patients. No risk-reduction strategy is proven to reduce mortality rates of women at increased risk for ovarian cancer. Methods of ovarian cancer surveillance are unproven in high-risk women. According to some studies, the use of oral contraceptives in high-risk women reduces ovarian cancer risk. Prophylactic salpingo-oophorectomy is the most effective method of cancer risk reduction in women at high risk for ovarian cancer. However, women who undergo prophylactic salpingo-oophorectomy remain at risk for primary peritoneal cancer. A minority of women with BRCA1 and BRCA2 mutations are diagnosed with occult cancer at the time of surgical prophylaxis. Surgical prophylaxis should include complete removal of the fallopian tubes and ovaries, procurement of peritoneal cytology, and thorough evaluation of the tubes and ovaries by an expert pathologist. Beginning at age 30 years, women with BRCA1 and BRCA2 germline mutations should have an annual or semiannual screening, consisting of serum CA-125 measurement and transvaginal ultrasound, until the completion of childbearing. After the completion of childbearing and by age 40 years, women should undergo prophylactic salpingo-oophorectomy.

Entities:  

Mesh:

Year:  2003        PMID: 12594936     DOI: 10.1007/s11864-003-0011-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  42 in total

1.  Oophorectomy in carriers of BRCA mutations.

Authors:  Sen H Zhuang; Gregory D Leonard; Sandra M Swain
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

Review 2.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

Authors:  W Burke; M Daly; J Garber; J Botkin; M J Kahn; P Lynch; A McTiernan; K Offit; J Perlman; G Petersen; E Thomson; C Varricchio
Journal:  JAMA       Date:  1997-03-26       Impact factor: 56.272

3.  Psychological impact of screening for familial ovarian cancer: reactions to initial assessment.

Authors:  G Erlick Robinson; B P Rosen; L N Bradley; W G Rockert; M L Carr; D E Cole; K J Murphy
Journal:  Gynecol Oncol       Date:  1997-05       Impact factor: 5.482

4.  Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.

Authors:  Mariëlle S van Roosmalen; Lia C G Verhoef; Peep F M Stalmeier; Nicoline Hoogerbrugge; Willem A J van Daal
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

5.  Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

Authors:  V R Grann; K S Panageas; W Whang; K H Antman; A I Neugut
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

6.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Authors:  Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

7.  Papillary peritoneal carcinomatosis after prophylactic oophorectomy.

Authors:  G M Kemp; J G Hsiu; M C Andrews
Journal:  Gynecol Oncol       Date:  1992-12       Impact factor: 5.482

8.  The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer.

Authors:  T H Bourne; S Campbell; K Reynolds; J Hampson; L Bhatt; T J Crayford; M I Whitehead; W P Collins
Journal:  Gynecol Oncol       Date:  1994-03       Impact factor: 5.482

9.  Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study.

Authors:  S E Hankinson; D J Hunter; G A Colditz; W C Willett; M J Stampfer; B Rosner; C H Hennekens; F E Speizer
Journal:  JAMA       Date:  1993-12-15       Impact factor: 56.272

10.  Endometrial and ovarian cancer and oral contraceptives--findings in a large cohort study.

Authors:  M P Vessey; R Painter
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more
  1 in total

1.  Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Authors:  Victor R Grann; Priya R Patel; Judith S Jacobson; Ellen Warner; Daniel F Heitjan; Maxine Ashby-Thompson; Dawn L Hershman; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2010-07-20       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.